ReviewDermatology and therapy2023
Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success.
Review in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost-effective omalizumab dosage for chronic urticaria: a systematic review and network meta-analysis.Archives of dermatological research · 2024Pooled it
- Article
- Knowledge of chronic spontaneous urticaria management among Italian general practitioners: Baseline findings from the BRIDGE study.The World Allergy Organization journal · 2026Article
- Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.Dermatology and therapy · 2026Article
- Baseline disease duration of chronic spontaneous urticaria participants in phase III clinical trials.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026Article
- ActiveJournal of clinical medicine research · 2026Article
- Targeting Mast Cells in Chronic Spontaneous Urticaria.Current allergy and asthma reports · 2026Review
- Clinical profile, prevalence, and burden of chronic spontaneous urticaria in the United States.The World Allergy Organization journal · 2025Article
- Dermatologists' knowledge, attitudes, and practices regarding omalizumab therapy for chronic urticaria.Archives of dermatological research · 2025Article
- Sexual Dysfunction in Chronic Urticaria: A Systematic Review.Dermatology and therapy · 2025Review
- Chronic spontaneous urticaria: update on pathogenesis and therapeutic implications.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic spontaneous urticaria (CSU) is a complex skin disease characterized by the spontaneous appearance of wheals, angioedema, or both, for more than 6 weeks. Many patients experience a relapsing-remitting disease course for years. Owing to the unpredictability of wheal recurrence and the severity of pruritis, patients suffer considerable impairment in their quality of life. Physicians face multiple challenges, not least of which is a lack of clear guidance on what constitutes "treatment success". There is a lack of awareness of which measures should be used to best assess the various aspects of CSU, including disease activity, disease control, and quality of life-which themselves each comprise multiple components-and how to apply the results of each score to treatment decision-making. Although the overarching aim of treatment is for patients to be completely free of signs and symptoms of CSU, a more realistic definition of "treatment success" is needed to guide ongoing, long-term disease management for each individual patient. In this review, we consider what lessons can be learned from the current evidence base to provide further direction toward a universal definition of "treatment success".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.